ACTR-06. CLINICAL TRIAL OF VAL-083 IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM: HALF-WAY REPORT

Approximately 60% of glioblastoma multiforme (GBM) patients possess an unmethylated methylguanine DNA-methyltransferase (MGMT gene, which confers a limited response to standard of care treatment with temozolomide (TMZ) resulting in a lower survival. VAL-083 is a novel bi-functional DNA targeting age...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Chen, Zhong-ping, Guo, Chengcheng, Yang, Qun-ying, Li, Jia-wei, Wu, Shao-xiong, Bacha, Jeffrey, Johnson, Gregory, Langlands, John, Kwan, Claire, Kanekal, Sarath, Schwartz, Richard, Lopez, Lorena, Brown, Dennis
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2019
Konular:
Adult Clinical Trials - Non-Immunologic
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847153/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.050
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller